Nature

NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms

Myxoid and round cell liposarcomas constitute approximately one-third of all liposarcomas, a relatively common group of fat-derived soft tissue sarcomas. 1 The peak incidence of myxoid and round cell ...
Nature

NY-ESO-1 antibody as a novel tumour marker of gastric cancer

NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer. NY-ESO ...
The New England Journal of Medicine

Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with ...
ascopubs.org

A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical ...

A phase II study of personalized selection of peptide vaccines combined with conventional chemo- or endocrine therapy for refractory breast cancer. Background: This is a first-in-human phase I study ...
ascopubs.org

Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.

Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors. Phase I/II study of stereotactic ...